The organisation, an independent clinical research facility founded in 2009, will quadruple capacity through the move.
Highlights of the new facility include a 100-bed Phase I unit, a 16-bed Intensive Procedural Unit (IPU), and an additional 5,000 square feet of dedicated space for Phase II-IV trials.
Advanced Pharma CEO Samantha Amaba told Outsourcing-pharma.com the firm has seen strong demand for all types of trials, particularly for Phase II to IV studies.
“[The UMLSTP site] provides the exact platform and amenities that we have been seeking,” she explained, adding that it would further facilitate the organisation's efforts to network with the University of Miami and, its research faculty, the Jackson Health System.
This was echoed by spokeswoman ABBY Symonds who told Outsourcing-pharma.com that growing demand the organisation had seen over the last few years meant that its existing site, also in Miami, had “almost been bursting at the seams.”